First Bank & Trust Acquires New Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

First Bank & Trust acquired a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 7,471 shares of the company’s stock, valued at approximately $205,000.

A number of other institutional investors have also made changes to their positions in the stock. Handelsbanken Fonder AB raised its stake in shares of BridgeBio Pharma by 16.6% in the 4th quarter. Handelsbanken Fonder AB now owns 37,950 shares of the company’s stock valued at $1,041,000 after acquiring an additional 5,400 shares in the last quarter. State of New Jersey Common Pension Fund D increased its position in BridgeBio Pharma by 21.6% in the 4th quarter. State of New Jersey Common Pension Fund D now owns 93,131 shares of the company’s stock worth $2,556,000 after buying an additional 16,545 shares during the period. Rhumbline Advisers increased its position in BridgeBio Pharma by 2.3% in the 4th quarter. Rhumbline Advisers now owns 219,120 shares of the company’s stock worth $6,013,000 after buying an additional 5,007 shares during the period. Legato Capital Management LLC bought a new position in BridgeBio Pharma in the 4th quarter worth approximately $210,000. Finally, Harvey Capital Management Inc. bought a new position in BridgeBio Pharma in the 4th quarter worth approximately $354,000. 99.85% of the stock is owned by institutional investors.

BridgeBio Pharma Price Performance

Shares of BBIO stock opened at $36.81 on Friday. The stock’s fifty day simple moving average is $31.71 and its 200 day simple moving average is $27.85. The firm has a market cap of $6.96 billion, a price-to-earnings ratio of -15.27 and a beta of 1.07. BridgeBio Pharma, Inc. has a one year low of $21.62 and a one year high of $39.47.

BridgeBio Pharma (NASDAQ:BBIO) last announced its quarterly earnings results on Thursday, February 20th. The company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($1.09) by ($0.22). On average, research analysts anticipate that BridgeBio Pharma, Inc. will post -2.56 earnings per share for the current year.

Insider Activity at BridgeBio Pharma

In other BridgeBio Pharma news, major shareholder Global Investors Lp Viking sold 3,065,616 shares of BridgeBio Pharma stock in a transaction on Friday, January 31st. The stock was sold at an average price of $34.90, for a total value of $106,989,998.40. Following the completion of the transaction, the insider now owns 22,055,375 shares in the company, valued at approximately $769,732,587.50. The trade was a 12.20 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Brian C. Stephenson sold 68,000 shares of BridgeBio Pharma stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $36.29, for a total value of $2,467,720.00. Following the completion of the transaction, the chief financial officer now owns 93,758 shares of the company’s stock, valued at approximately $3,402,477.82. The trade was a 42.04 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 3,496,239 shares of company stock valued at $122,612,036 in the last 90 days. 24.66% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. Evercore ISI lifted their price target on BridgeBio Pharma from $45.00 to $50.00 and gave the stock an “outperform” rating in a research report on Monday, December 23rd. Bank of America lifted their price target on BridgeBio Pharma from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, November 25th. HC Wainwright reaffirmed a “buy” rating and issued a $49.00 price target on shares of BridgeBio Pharma in a research report on Thursday, February 13th. Finally, Scotiabank lifted their price target on BridgeBio Pharma from $48.00 to $49.00 and gave the stock a “sector outperform” rating in a research report on Wednesday, February 12th. One analyst has rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $49.08.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.